SG10201913746RA - Anti-cd3-folate conjugates and their uses - Google Patents
Anti-cd3-folate conjugates and their usesInfo
- Publication number
- SG10201913746RA SG10201913746RA SG10201913746RA SG10201913746RA SG10201913746RA SG 10201913746R A SG10201913746R A SG 10201913746RA SG 10201913746R A SG10201913746R A SG 10201913746RA SG 10201913746R A SG10201913746R A SG 10201913746RA SG 10201913746R A SG10201913746R A SG 10201913746RA
- Authority
- SG
- Singapore
- Prior art keywords
- folate conjugates
- folate
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250451P | 2015-11-03 | 2015-11-03 | |
| US201562267086P | 2015-12-14 | 2015-12-14 | |
| US201662374693P | 2016-08-12 | 2016-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913746RA true SG10201913746RA (en) | 2020-03-30 |
Family
ID=58662682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803211TA SG11201803211TA (en) | 2015-11-03 | 2016-11-02 | Anti-cd3-folate conjugates and their uses |
| SG10201913746RA SG10201913746RA (en) | 2015-11-03 | 2016-11-02 | Anti-cd3-folate conjugates and their uses |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803211TA SG11201803211TA (en) | 2015-11-03 | 2016-11-02 | Anti-cd3-folate conjugates and their uses |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11851488B2 (en) |
| EP (1) | EP3370771A4 (en) |
| JP (2) | JP6931649B2 (en) |
| KR (1) | KR20180077271A (en) |
| CN (1) | CN108348603B (en) |
| AU (1) | AU2016349786B2 (en) |
| BR (1) | BR112018009004A8 (en) |
| CA (1) | CA3002573A1 (en) |
| IL (1) | IL258759B2 (en) |
| MX (1) | MX2018005232A (en) |
| SG (2) | SG11201803211TA (en) |
| WO (1) | WO2017079272A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2582108B (en) * | 2017-11-22 | 2022-08-17 | Geltor Inc | Methods and systems for engineering collagen |
| CN111417655A (en) * | 2018-08-28 | 2020-07-14 | 润俊(中国)有限公司 | anti-CD3 antibody folate bioconjugates and uses thereof |
| WO2020232165A1 (en) * | 2019-05-14 | 2020-11-19 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| TWI827807B (en) * | 2020-02-26 | 2024-01-01 | 香港商潤俊（中國）有限公司 | Anti-cd3 antibody folate bioconjugates and their uses |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| FR2504010B1 (en) | 1981-04-15 | 1985-10-25 | Sanofi Sa | ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| DE3377484D1 (en) | 1982-04-19 | 1988-09-01 | Nissan Motor | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| ATE66469T1 (en) | 1985-01-14 | 1991-09-15 | Neorx Corp | METAL RADIONUCLIDE LABELED PROTEIN FOR DIAGNOSIS AND THERAPY. |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
| NZ502375A (en) | 1997-07-14 | 2001-11-30 | Bolder Biotechnology Inc | The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| CA2348822A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| EP2226316B1 (en) | 2002-05-30 | 2016-01-13 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| CN101223272B (en) * | 2003-04-17 | 2013-04-03 | 斯克利普斯研究院 | Expanding the eukaryotic genetic code |
| EP1636340A4 (en) * | 2003-06-18 | 2009-02-11 | Scripps Research Inst | Unnatural reactive amino acid genetic code additions |
| GB0716160D0 (en) * | 2007-08-17 | 2007-09-26 | Biotransformations Ltd | Materials and methods for treating cancers which express folate receptors |
| JP2012034668A (en) | 2010-08-12 | 2012-02-23 | Tohoku Univ | Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof |
| CN103842383B (en) * | 2011-05-16 | 2017-11-03 | 健能隆医药技术（上海）有限公司 | Polyspecific FAB fusion proteins and its application method |
| SG195072A1 (en) * | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| JP6441079B2 (en) * | 2011-12-19 | 2018-12-19 | シンイミューン ゲーエムベーハー | Bispecific antibody molecule |
| US10968276B2 (en) * | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| RU2016104130A (en) * | 2013-07-12 | 2017-08-17 | Займворкс Инк. | SPECIFIC CONSTRUCTIONS BINDING CD3 AND CD19 ANTIGENS |
| EP2840091A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CN108431042A (en) * | 2015-11-02 | 2018-08-21 | 詹森药业有限公司 | Anti- IL1RAP antibody, in conjunction with the bispecific antigen binding molecules and application thereof of IL1RAP and CD3 |
| CN112384243A (en) * | 2018-04-17 | 2021-02-19 | 英温拉公司 | Trivalent trispecific antibody constructs |
| CN111417655A (en) * | 2018-08-28 | 2020-07-14 | 润俊(中国)有限公司 | anti-CD3 antibody folate bioconjugates and uses thereof |
| BR112021015832A2 (en) * | 2019-02-12 | 2022-01-18 | Ambrx Inc | Compositions containing antibody-tlr agonist conjugates, methods and uses thereof |
| WO2020168555A1 (en) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | Cd3 antigen binding fragment and application thereof |
-
2016
- 2016-11-02 US US15/773,167 patent/US11851488B2/en active Active
- 2016-11-02 KR KR1020187015756A patent/KR20180077271A/en active Search and Examination
- 2016-11-02 AU AU2016349786A patent/AU2016349786B2/en active Active
- 2016-11-02 MX MX2018005232A patent/MX2018005232A/en unknown
- 2016-11-02 CN CN201680064414.8A patent/CN108348603B/en active Active
- 2016-11-02 EP EP16862859.2A patent/EP3370771A4/en active Pending
- 2016-11-02 BR BR112018009004A patent/BR112018009004A8/en active Search and Examination
- 2016-11-02 WO PCT/US2016/060087 patent/WO2017079272A2/en active Application Filing
- 2016-11-02 SG SG11201803211TA patent/SG11201803211TA/en unknown
- 2016-11-02 JP JP2018522651A patent/JP6931649B2/en active Active
- 2016-11-02 CA CA3002573A patent/CA3002573A1/en active Pending
- 2016-11-02 IL IL258759A patent/IL258759B2/en unknown
- 2016-11-02 SG SG10201913746RA patent/SG10201913746RA/en unknown
-
2021
- 2021-08-16 JP JP2021132397A patent/JP7220755B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11851488B2 (en) | 2023-12-26 |
| EP3370771A4 (en) | 2019-06-19 |
| JP2018535972A (en) | 2018-12-06 |
| BR112018009004A2 (en) | 2018-10-30 |
| JP7220755B2 (en) | 2023-02-10 |
| WO2017079272A2 (en) | 2017-05-11 |
| EP3370771A2 (en) | 2018-09-12 |
| IL258759B2 (en) | 2023-04-01 |
| BR112018009004A8 (en) | 2019-02-26 |
| IL258759B (en) | 2022-12-01 |
| JP2021181487A (en) | 2021-11-25 |
| MX2018005232A (en) | 2018-08-15 |
| CN108348603B (en) | 2023-12-29 |
| CA3002573A1 (en) | 2017-05-11 |
| AU2016349786A1 (en) | 2018-06-21 |
| CN108348603A (en) | 2018-07-31 |
| WO2017079272A9 (en) | 2017-08-03 |
| US20180319885A1 (en) | 2018-11-08 |
| JP6931649B2 (en) | 2021-09-08 |
| IL258759A (en) | 2018-06-28 |
| KR20180077271A (en) | 2018-07-06 |
| SG11201803211TA (en) | 2018-05-30 |
| AU2016349786B2 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258248A (en) | Affinity-oligonucleotide conjugates and uses thereof | |
| IL285516B (en) | Amatoxin-antibody conjugates | |
| HK1256143A1 (en) | Aldehyde conjugates and uses thereof | |
| IL260323A (en) | Antibodies and conjugates thereof | |
| HK1251183A1 (en) | Bioconjugates and uses thereof | |
| GB201416112D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| IL265471A (en) | Affinity-oligonucleotide conjugates and uses thereof | |
| GB201513607D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| SG11201609490QA (en) | Polymer-flavonoid conjugate and uses thereof | |
| IL258759A (en) | Anti-cd3-folate conjugates and their uses | |
| ZA201608327B (en) | Curcumin-peptide conjugates and formulations thereof | |
| HK1247122A1 (en) | Combinations and uses thereof | |
| IL254241A0 (en) | Etv2 and uses thereof | |
| PT3544637T (en) | Nomv-antigen conjugates and use thereof | |
| HK1257229A1 (en) | Cck2r-drug conjugates | |
| PT3270711T (en) | Sugar-dipeptide conjugates | |
| SG10201506686WA (en) | Conjugates | |
| GB201517852D0 (en) | Novel compounds and conjugates | |
| GB201518839D0 (en) | Conjugates | |
| GB201513605D0 (en) | Pyrrolobenzodiazepine-antibody conjugates |